Literature DB >> 8044301

CA125-producing adenocarcinoma of the seminal vesicle.

T Ohmori1, K Okada, R Tabei, K Sugiura, S Nabeshima, H Ohoka, M Okamoto.   

Abstract

A case of primary seminal vesicle carcinoma is reported. The tumor was a CA125-producing adenocarcinoma consisting of fine papillary-tubular, intricate branching or anastomosing glandular structures and was composed of small cuboidal, but occasionally hobnailed, cells with mostly clear, but occasionally granular, cytoplasm. Some tumor cells showed evidence of secretion of seromucinous materials into the interpapillary and cystic space. Immunohistochemically, almost half of the tumor cells expressed a positive reaction with anti-CA125, a common serological marker for ovarian epithelial carcinomas; however, no tumor cells expressed any other serological tumor markers such as carcinoembryonic antigen, alpha-fetoprotein, human chorionic gonadotropin, prostatic specific acid phosphatase, or prostatic specific antigen. The patient showed a high level of serological CA125, which fluctuated parallel with the growth, removal and recurrence of the tumor. The morphological and immunohistochemical findings suggested a close relationship between the present tumor and clear cell carcinoma of the ovary, which is thought to be of a Müllerian-Wolfian duct origin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8044301     DOI: 10.1111/j.1440-1827.1994.tb03372.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  10 in total

1.  Variant prostate carcinoma and elevated serum CA-125.

Authors:  Mehmet Asim Bilen; Adriana Reyes; Deb Bhowmick; April Maa; Robert Bast; Louis L Pisters; Sue-Hwa Lin; Christopher J Logothetis; Shi-Ming Tu
Journal:  Can J Urol       Date:  2014-10       Impact factor: 1.344

Review 2.  Primary squamous cell carcinoma of seminal vesicle: an extremely rare case report with literature review.

Authors:  Jianzhong Wang; Xuan Yue; Ruining Zhao; Bochao Cheng; Romel Wazir; Kunjie Wang
Journal:  Int Urol Nephrol       Date:  2013-01-05       Impact factor: 2.370

3.  An unusual cause of hematospermia: Primary adenocarcinoma of the seminal vesicle.

Authors:  Alper Eken; Volkan Izol; I Atilla Aridogan; Seyda Erdogan; Arbil Acıkalın; Zuhtu Tansug
Journal:  Can Urol Assoc J       Date:  2012-12       Impact factor: 1.862

4.  Metastatic primary seminal vesicle adenocarcinoma: management of a rare tumour with multiagent chemotherapy and hormonal therapy.

Authors:  Hira Lal; Priyank Yadav; Rahul Jena; Manoj Jain
Journal:  BMJ Case Rep       Date:  2017-10-10

Review 5.  Primary seminal vesicle adenocarcinoma: a lethal yet cryptic malignancy with review of literature.

Authors:  Abhishek Bhat; Indraneel Banerjee; Oleksandr N Kryvenko; Ramgopal Satyanarayana
Journal:  BMJ Case Rep       Date:  2019-12-17

6.  Congenital anomalies of the genitourinary system can help in diagnosis of the primary site of metastatic cancer: a case report and a review of the literature.

Authors:  Andrzej Deptala; Agnieszka Romanowicz; Aleksandra Czerw; Jerzy Walecki; Wojciech Rogowski; Anna Nasierowska-Guttmejer
Journal:  Onco Targets Ther       Date:  2016-07-20       Impact factor: 4.147

7.  Primary adenocarcinoma of the seminal vesicle.

Authors:  Safae Terrisse; Maria Eugenia Camblor; Jérôme Vérine; Hélène Gauthier; Pierre Mongiat-Artus; Stéphane Culine
Journal:  Rare Tumors       Date:  2017-10-03

8.  A 5-year follow-up of primary seminal vesicle adenocarcinoma: A case report.

Authors:  Tiejun Yin; Yueqiang Jiang
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

9.  Adenocarcinoma of the seminal vesicles complicated by antineutrophil cytoplasmic antibody vasculitis: a case report and review of the literature.

Authors:  Hazel Lote; Ethna Mannion; Terence Cook; Thomas Cairns; Philip Savage
Journal:  J Med Case Rep       Date:  2013-03-01

10.  Primary adenocarcinoma of the seminal vesicle.

Authors:  M Tarján; I Ottlecz; T Tot
Journal:  Indian J Urol       Date:  2009-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.